¿Sobreutilización de corticoides en las exacerbaciones de pacientes con enfermedad pulmonar obstructiva crónica?

  1. Gallego Muñoz, Cristóbal
  2. Olmos Gutiérrez, Luis
  3. Onteniente Candela, María
  4. Iniesta Navalón, Carles
Revista:
Journal of Negative and No Positive Results: JONNPR

ISSN: 2529-850X

Año de publicación: 2018

Volumen: 3

Número: 2

Páginas: 144-145

Tipo: Artículo

DOI: 10.19230/JONNPR.2073 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Journal of Negative and No Positive Results: JONNPR

Referencias bibliográficas

  • Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379:1341-51.
  • Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A et al. Predictors of adverse outcome in patients hospitalised for exacerbation of COPD. Respiration. 2012; 84:17-26.
  • Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003; 348:2618-25.
  • Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001; 163: 1256-76.
  • Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW et al., Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerba-tions of chronic obstructive pulmonary disease. N Engl J Med. 1999; 340:1941-7.
  • De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, van den Berg JWK. Oral or IV prednisolone in the treatment of COPD exacerbations: A randomized, controlled, double-blind study. Chest. 2007; 132:1741-7.
  • Ding Z, Li X, Lu Y, Rong G, Yang R, Zhang R et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exa-cerbation of chronic obstructive pulmonary disease. Respir Med. 2016; 121:39-47.
  • Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Phar-macological treatment of stable chronic obstructive pulmonary disease. Arch Bronconeumol. 2017; 53:324-35.
  • Pozo-Rodríguez F, López-Campos JL, Álvarez-Martínez CJ, Castro- Acosta A, Agüero R, Hueto J et al. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012; 7:e42156.
  • Rueda-Camino JA, Bernal-Bello D, Canora-Lebrato J, Velázquez- Ríos L, García de Viedma-García V, Guerrero-Santillán M et al. Dosis altas de corticoides sistémicos en pacientes ingresados por exacerbación de EPOC. Un estudio de cohortes. Rev Clin Esp. 2017 (artículo en prensa).
Fuente de los datos: Dialnet